AmSurg (NASDAQ:AMSG) Has Just Had Its Target Increased by Researchers at KeyBanc Capital Markets to $92.00

Share

Stock Analysis:AmSurg (NASDAQ:AMSG) Stock Target Has Been Increased

In analysts note revealed to clients and investors by KeyBanc Capital Markets on 3 December, AmSurg (NASDAQ:AMSG) had its target price upgraded to $92.00. The firm presently has a solid Overweight rating on shares.

From a total of 12 analysts covering AmSurg (NASDAQ:AMSG) stock, 11 rate it a ”Buy”, 1 a “Sell”, and 0 a ”Hold”. This means that 92% of the ratings are positive. The highest target price is $101 while the lowest target price is $70. The mean of all analyst targets is $92 with a 15.06% above today’s ($80.39) stock price. AmSurg was the topic of 4 analyst reports since August 6, 2015 according to the firm StockzIntelligence Inc. Goldman Sachs reinitiated shares on November 30 with “Buy” rating.

Approximately 909,949 shares of stock traded hands. Amsurg Corp (NASDAQ:AMSG) has risen 27.50% since April 30, 2015 and is uptrending. It has outperformed by 27.79% the S&P500.

AmSurg Corp. is the owner and operator of ambulatory surgery centers in the United States. The company has a market cap of $3.86 billion. The Firm is also a well-known provider of outsourced physician services in the areas of anesthesiology, children’s services, emergency medicine and radiology. It has 34.07 P/E ratio. The Firm operates in two divisions: ambulatory surgery services and outsourced physician services.

According to Zacks Investment Research, “AmSurg Corp. is in the business of developing, acquiring and operating practice-based ambulatory surgery centers, in partnerships with physician practice groups, throughout the United States. An AmSurg surgery center is typically located adjacent to or in the immediate vicinity of the specialty medical practice of a physician group partner’s office. Each of the surgery centers provides a narrow range of high volume, lower-risk surgical procedures, generally in a single specialty.” Get a free copy of the Zacks research report on Amsurg Corp (AMSG).

COMMENTS: